Jasper Therapeutics, Inc. (JSPR) is a clinical-stage biotechnology company based in Redwood City, California, developing biologic therapies for immune-mediated diseases. Its pipeline includes the dual-complement inhibitor vensobafusp alfa (KP-104), the anti-KIT antibody briquilimab, and the preclinical asset KP-701. In midday trading on Wednesday, the shares rose 9.48% to $11.32, compared with the prior session's close of $10.34, confirming an upward move. No verified company-specific news or fundamental development explained the gain; the price action is best characterized as a rebound following two consecutive double-digit declines.
No verified news or fundamental catalyst found for Wednesday's advance. The company has issued no press release since its November 16 third-quarter results and November 9 warrant tender announcement, and no regulatory filing or clinical readout was published before the move. With no new information to reprice the equity, the gain is most consistent with a mechanical rebound after an extreme two-session selloff: the stock fell 13.96% on Monday and 12.15% on Tuesday, losing roughly 24% in two days and about 39% from its November 6 post-split close of $16.86. Tuesday's intraday low of $9.25 was a 52-week low. Bounces of this size are common in a name that has averaged a 4.36% absolute daily move over the past three months.
Verified sell-side commentary published before Wednesday's session did provide modest support, though not enough to justify a move of this magnitude on its own. Piper Sandler lowered its price target to $44 from $60 while maintaining an Overweight rating, explicitly attributing the change to the 1-for-30 reverse split rather than to deteriorating fundamentals, and reiterated that the IgA nephropathy Stage 1 readout remains the key value driver. H.C. Wainwright reiterated a Buy rating, and Rodman & Renshaw reaffirmed Buy on Tuesday evening with its target under review pending an updated model. A cluster of maintained bullish ratings after a sharp drawdown can stabilize sentiment, but none represented new data.
The structural backdrop amplifies ordinary order flow. After the 1-for-30 consolidation, only about 1.11 million common shares are outstanding, giving the stock a market capitalization near $13 million on that share base. Average daily turnover is roughly 18,000 shares, so modest buying can move the quote by several percentage points. Wednesday's advance is consistent with thin liquidity and dip-buying interest rather than a re-rating, and volume has been tracking below the recent average pace.
The gain was not part of a sector move. The SPDR S&P Biotech ETF (XBI) was up about 0.2% and the iShares Biotechnology ETF (IBB) was down about 0.3%, leaving JSPR far ahead of its peer group. Volume, while light against the roughly 18,000-share average, was concentrated in a stock whose bid-ask spread remains wide after the split. Technically, the shares bounced off the $9.25 low and pushed back above $11, but they remain far below the post-split $16.86 close from November 6 and below any meaningful moving average, so the move reads as a counter-trend bounce inside a persistent downtrend rather than a breakout.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Jasper Therapeutics earns 22 out of 100. The verified news flow was weak: maintained analyst ratings and a split-adjusted price target cut carry little materiality for a company with no product revenue and a market value near $13 million. The price move was also unremarkable by this stock's standards, roughly 2.2 times its typical 4.36% daily swing, with eight larger single-session moves in the last 69 sessions. Weak news plus an ordinary-for-this-name move produces a low score.
The central near-term event is the Stage 1 interim readout from the Phase 2 renal basket study of vensobafusp alfa in IgA nephropathy, guided for the fourth quarter of 2026, with additional data expected in mid-2027. Enrollment has begun in C3G/IC-MPGN cohorts, and an FSGS cohort is slated to start in the first quarter of 2027. A special shareholder meeting adjourned for lack of quorum reconvenes December 1, a procedural item worth monitoring. Investors will also weigh a $135.3 million cash position against ongoing burn and the recent departure of the chief financial officer, offset by interim appointments. Risks include clinical failure, further dilution, and continued listing-compliance pressure.
Tickeron's Trending AI Robots page curates the platform's best-performing automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers earn a place in this section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup rotates as conditions change. Reviewing the trending list is a practical way to see which approaches are working now and to compare them against your own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The RSI Indicator for JSPR moved into overbought territory on November 17, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
JSPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JSPR as a result. In 85 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for JSPR turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 36 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for JSPR entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.592). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology